Cathie Wood’s Aggressive Growth Strategy Pays Off
After a few choppy years, Cathie Wood’s investment portfolio is finally gaining momentum. The Ark Invest co-founder, CEO, and chief investment officer has been making strategic moves across her aggressive growth exchange-traded funds. Wood’s latest investments are worth taking a closer look at.
A Leader in Programmatic Advertising
Ark Invest added to its existing position in The Trade Desk, a company that has been soaring high this year. Despite delivering a “beat and raise” performance in its third-quarter update, the stock fell 6% due to high expectations. However, the company’s revenue rose 27% to $628 million, beating Wall Street’s estimates. The Trade Desk’s adjusted earnings also climbed 24% to $0.41 a share, exceeding analyst expectations.
The Future of Advertising is Here
The Trade Desk’s strong performance can be attributed to its leadership in connected TV and other ad platforms that are gaining popularity. The company’s customer retention rate of at least 95% is a testament to its ability to help marketers reach a wide audience. As the advertising landscape continues to evolve, The Trade Desk is well-positioned to thrive.
A Bet on the Future of Medical Solutions
Wood has also invested in Pacific Biosciences of California, a leader in long-read gene sequencing. Although the company’s quarterly results were not as impressive as The Trade Desk’s, its revenue is expected to grow next year, and its losses are expected to narrow significantly. Pacific Biosciences is taking steps towards achieving profitability, making it an attractive investment opportunity.
Oncological Tests Developer Soars High
Finally, there’s Guardant Health, a developer of oncological tests that has been making waves in the medical solutions space. The company’s revenue rose 34% to $191.5 million, blasting through analyst estimates. Guardant Health also posted a much smaller loss than expected and boosted its full-year guidance. With a strong balance sheet and a promising pipeline of clinical or biopharmaceutical tests, Guardant Health is an attractive investment opportunity.
Don’t Miss Out on the Next Big Thing
Investing in the right companies at the right time can lead to significant returns. By following Cathie Wood’s aggressive growth strategy, investors can tap into the potential of companies like The Trade Desk, Pacific Biosciences of California, and Guardant Health.
Leave a Reply